CADL Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Stats
Today's Volume	663 877
Average Volume	5.36M
Market Cap	177.55M
EPS	$-0.290 ( 2023-11-09 )
Next earnings date	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.62
ATR14	$0.0260 (0.43%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-12	Schoch Charles	Sell	0	Common Stock
2024-01-12	Schoch Charles	Sell	0	Common Stock
2024-01-12	Schoch Charles	Sell	25 000	Stock Option (Right to Buy)
2024-01-12	Schoch Charles	Sell	39 498	Stock Option (Right to Buy)
2023-11-28	Tyagarajan Seshu	Sell	17 328	Common Stock

INSIDER POWER
76.64
Last 92 transactions
Buy: 8 106 969 \| Sell: 4 393 086

Volume Correlation

Long: -0.07 (neutral)

Short: 0.37 (neutral)

Signal:(53.12) Neutral

Candel Therapeutics, Inc. Correlation

10 Most Positive Correlations
SRTS	0.913
CNDT	0.905
SYBX	0.89
CPIX	0.89
PSTV	0.879
FOSL	0.877
ATHE	0.87
EWTX	0.863
IMAB	0.861
LPCN	0.86

10 Most Negative Correlations
TYHT	-0.863
AMRB	-0.848
IMRA	-0.845
RDUS	-0.838
XOG	-0.827
RDI	-0.825
VERX	-0.825
SGEN	-0.824
MPRA	-0.822
ZGNX	-0.821

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Candel Therapeutics, Inc. Correlation - Currency/Commodity

0.50
( weak )

0.29
( neutral )

0.00
( neutral )

0.57
( weak )

0.11
( neutral )

-0.50
( neutral )

Candel Therapeutics, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-1.20M (0.00 %)
EPS:	$-1.310

Q4	2023
Revenue:	$0
Gross Profit:	$-312 000 (0.00 %)
EPS:	$-0.380

Q3	2023
Revenue:	$0
Gross Profit:	$-306 000 (0.00 %)
EPS:	$-0.290

Q2	2023
Revenue:	$0
Gross Profit:	$-295 000 (0.00 %)
EPS:	$-0.330

Financial Reports:

No articles found.

Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.